Document is current
Any future updates will be listed below
-
Authors
Beckers, Jimmy https://orcid.org/0000-0003-2484-6556
Tharkeshwar, Arun Kumar https://orcid.org/0000-0002-5529-9754
Fumagalli, Laura https://orcid.org/0000-0002-9333-926X
Contardo, Matilde https://orcid.org/0000-0002-6160-4911
Van Schoor, Evelien https://orcid.org/0000-0003-2637-2761
Fazal, Raheem https://orcid.org/0000-0001-8833-9997
Thal, Dietmar Rudolf https://orcid.org/0000-0002-1036-1075
Chandran, Siddharthan https://orcid.org/0000-0001-6827-1593
Mancuso, Renzo https://orcid.org/0000-0002-7046-3348
Van Den Bosch, Ludo https://orcid.org/0000-0003-0104-4067
Van Damme, Philip https://orcid.org/0000-0002-4010-2357
- License Information
-
More Information
Article History
Received: 28 August 2023
Accepted: 30 August 2023
First Online: 18 September 2023
Declarations
:
: Ethical approval for the study was given by the Ethical Committee of UZ Leuven (S65097, S59292, S60803, S50354, Leuven, Belgium).
: D.R.T. received consultant speaker honorary from Novartis (Switzerland), Biogen (USA), travel reimbursement from GE-Healthcare (UK), UCB (Belgium) and collaborated with Novartis Pharma AG (Switzerland), Probiodrug (Germany), GE-Healthcare (UK), and Janssen Pharmaceutical Companies (Belgium). None related to the work in this paper. R.M. has scientific collaborations with Alector, Nodthera and Alchemab and had consultant activities for Sanofi during 2022. L.V.D.B. is head of the Scientific Advisory Board of Augustine Therapeutics (Leuven, Belgium) and is part of the Investment Advisory Board of Droia Ventures (Meise, Belgium).
